Efficacy of Continuing Anti-Angiogenic Agents in the Second-Line Treatment for Metastatic Colon Cancer Depending on the KRAS Mutation Status: A Meta-Analysis
Colorectal Oncology
doi 10.17650/2220-3478-2018-8-2-38-45
Full Text
Open PDFAbstract
Available in full text
Date
July 12, 2018
Authors
Publisher
Publishing House ABV Press